

Titan Abamectin 18 (Titan Abamectin 18 Insecticide / Miticide)

Titan Ag

Chemwatch: 8580-715

Version No: 3.1

Safety Data Sheet according to Work Health and Safety Regulations (Hazardous Chemicals) 2023 and ADG requirements

Chemwatch Hazard Alert Code: 3

Initial Date: 31/12/2025

Revision Date: 30/04/2026

Print Date: 03/06/2026

L.GHS.AUS.EN.E

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product Identifier

Product name	Titan Abamectin 18 (Titan Abamectin 18 Insecticide / Miticide)
Chemical Name	Not Applicable
Synonyms	Not Available
Proper shipping name	PESTICIDE, LIQUID, TOXIC, N.O.S. (contains abamectin)
Chemical formula	Not Applicable
Other means of identification	Not Available

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Agricultural miticide and insecticide.
--------------------------	--

Details of the manufacturer or importer of the safety data sheet

Registered company name	Titan Ag
Address	Princes Street Marina, Suite 15/16 Princes Street Newport NSW 2106 Australia
Telephone	+61 2 9999 6655
Fax	+61 2 9999 0483
Website	https://www.titanag.com.au/
Email	titanorders@titanag.com.au

Emergency telephone number

Association / Organisation	Titan Ag
Emergency telephone number(s)	1800 033 111 (24 hours)
Other emergency telephone number(s)	Not Available

SECTION 2 Hazards identification

Classification of the substance or mixture

COMBUSTIBLE LIQUID, regulated for storage purposes only

Poisons Schedule	S6
Classification ^[1]	Acute Toxicity (Oral) Category 2, Skin Corrosion/Irritation Category 2, Serious Eye Damage/Eye Irritation Category 2A, Acute Toxicity (Inhalation) Category 3, Specific Target Organ Toxicity - Single Exposure (Respiratory Tract Irritation) Category 3, Reproductive Toxicity Category 1A, Specific Target Organ Toxicity - Repeated Exposure Category 2, Hazardous to the Aquatic Environment Long-Term Hazard Category 1
Legend:	1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI

Label elements

Hazard pictogram(s)	  
Signal word	Danger

Hazard statement(s)

Titan Abamectin 18 (Titan Abamectin 18 Insecticide / Miticide)

H300	Fatal if swallowed.
H315	Causes skin irritation.
H319	Causes serious eye irritation.
H331	Toxic if inhaled.
H335	May cause respiratory irritation.
H360FD	May damage fertility. May damage the unborn child.
H373	May cause damage to organs through prolonged or repeated exposure.
H410	Very toxic to aquatic life with long lasting effects.

Precautionary statement(s) Prevention

P202	Do not handle until all safety precautions have been read and understood.
P260	Do not breathe mist/vapours/spray.
P264	Wash all exposed external body areas thoroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P280	Wear protective gloves, protective clothing, eye protection and face protection.
P273	Avoid release to the environment.

Precautionary statement(s) Response

P301+P310	IF SWALLOWED: Immediately call a POISON CENTER/doctor/physician/first aider.
P308+P313	IF exposed or concerned: Get medical advice/ attention.
P330	Rinse mouth.
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P304+P340	IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P311	Call a POISON CENTER/doctor/physician/first aider.
P337+P313	If eye irritation persists: Get medical advice/attention.
P391	Collect spillage.
P302+P352	IF ON SKIN: Wash with plenty of water.
P332+P313	If skin irritation occurs: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before reuse.

Precautionary statement(s) Storage

P403+P233	Store in a well-ventilated place. Keep container tightly closed.
P405	Store locked up.

Precautionary statement(s) Disposal

P501	Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.
------	--

No further product hazard information.

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
872-50-4	28	N-methyl-2-pyrrolidone
71751-41-2	1.8	abamectin
Legend:	1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L; * EU IOELVs available	

SECTION 4 First aid measures

Description of first aid measures

Eye Contact	If this product comes in contact with the eyes: - Immediately hold eyelids apart and flush the eye continuously with running water. - Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. - Continue flushing until advised to stop by the Poisons Information Centre or a doctor, or for at least 15 minutes. - Transport to hospital or doctor without delay. - Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	If skin contact occurs: - Immediately remove all contaminated clothing, including footwear. - Flush skin and hair with running water (and soap if available). - Seek medical attention in event of irritation.
Inhalation	- If fumes or combustion products are inhaled remove from contaminated area. - Lay patient down. Keep warm and rested. - Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures.

Continued...

Titan Abamectin 18 (Titan Abamectin 18 Insecticide / Miticide)

	▶ Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary. ▶ Transport to hospital, or doctor, without delay.
Ingestion	▶ IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY. ▶ For advice, contact a Poisons Information Centre or a doctor. ▶ Urgent hospital treatment is likely to be needed. ▶ In the mean time, qualified first-aid personnel should treat the patient following observation and employing supportive measures as indicated by the patient's condition. ▶ If the services of a medical officer or medical doctor are readily available, the patient should be placed in his/her care and a copy of the SDS should be provided. Further action will be the responsibility of the medical specialist. ▶ If medical attention is not available on the worksite or surroundings send the patient to a hospital together with a copy of the SDS. Where medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise: ▶ INDUCE vomiting with fingers down the back of the throat, ONLY IF CONSCIOUS. Lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. NOTE: Wear a protective glove when inducing vomiting by mechanical means.

Indication of any immediate medical attention and special treatment needed

For abamectin (avermectins):
Toxicity following accidental ingestion may be minimised by emesis-induction within one half hour of exposure. Since abamectin is thought to bind to glutamate-gated chloride ion channels, it is probably wise to avoid drugs that also interact with other ligand-gated chloride channels, including those that enhance GABA activity in patients with potentially toxic abamectin exposure
Avoid drugs that enhance GABA activity (barbiturate, benzodiazepines, valproic acid, etc.).
As in all cases of suspected poisoning, follow the ABCDEs of emergency medicine (airway, breathing, circulation, disability, exposure), then the ABCDEs of toxicology (antidotes, basics, change absorption, change distribution, change elimination).
For poisons (where specific treatment regime is absent):

BASIC TREATMENT

- ▶ Establish a patent airway with suction where necessary.
- ▶ Watch for signs of respiratory insufficiency and assist ventilation as necessary.
- ▶ Administer oxygen by non-rebreather mask at 10 to 15 L/min.
- ▶ Monitor and treat, where necessary, for pulmonary oedema.
- ▶ Monitor and treat, where necessary, for shock.
- ▶ Anticipate seizures.
- ▶ **DO NOT** use emetics. Where ingestion is suspected rinse mouth and give up to 200 ml water (5 ml/kg recommended) for dilution where patient is able to swallow, has a strong gag reflex and does not drool.

ADVANCED TREATMENT

- ▶ Consider orotracheal or nasotracheal intubation for airway control in unconscious patient or where respiratory arrest has occurred.
- ▶ Positive-pressure ventilation using a bag-valve mask might be of use.
- ▶ Monitor and treat, where necessary, for arrhythmias.
- ▶ Start an IV D5W TKO. If signs of hypovolaemia are present use lactated Ringers solution. Fluid overload might create complications.
- ▶ Drug therapy should be considered for pulmonary oedema.
- ▶ Hypotension with signs of hypovolaemia requires the cautious administration of fluids. Fluid overload might create complications.
- ▶ Treat seizures with diazepam.
- ▶ Proparacaine hydrochloride should be used to assist eye irrigation.

BRONSTEIN, A.C. and CURRANCE, P.L.
EMERGENCY CARE FOR HAZARDOUS MATERIALS EXPOSURE: 2nd Ed. 1994

SECTION 5 Firefighting measures

Extinguishing media

- ▶ Water spray or fog.
- ▶ Foam.
- ▶ Dry chemical powder.
- ▶ BCF (where regulations permit).
- ▶ Carbon dioxide.

Special hazards arising from the substrate or mixture

Fire Incompatibility	▶ Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result
----------------------	--

Advice for firefighters

Fire Fighting	▶ Alert Fire Brigade and tell them location and nature of hazard. ▶ Wear full body protective clothing with breathing apparatus. ▶ Prevent, by any means available, spillage from entering drains or water course. ▶ Use fire fighting procedures suitable for surrounding area. ▶ Do not approach containers suspected to be hot. ▶ Cool fire exposed containers with water spray from a protected location. ▶ If safe to do so, remove containers from path of fire. ▶ Equipment should be thoroughly decontaminated after use.
Fire/Explosion Hazard	▶ Combustible. ▶ Slight fire hazard when exposed to heat or flame. ▶ Heating may cause expansion or decomposition leading to violent rupture of containers. ▶ On combustion, may emit toxic fumes of carbon monoxide (CO). ▶ May emit acid smoke. ▶ Mists containing combustible materials may be explosive. Combustion products include: ▶ carbon dioxide (CO2) nitrogen oxides (NOx) ▶ other pyrolysis products typical of burning organic material. May emit poisonous fumes.
HAZCHEM	2X

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

Minor Spills	Environmental hazard - contain spillage. - Remove all ignition sources. - Clean up all spills immediately. - Avoid breathing vapours and contact with skin and eyes. - Control personal contact with the substance, by using protective equipment. - Contain and absorb spill with sand, earth, inert material or vermiculite. - Wipe up. - Place in a suitable, labelled container for waste disposal.
Major Spills	Environmental hazard - contain spillage. - Clear area of personnel and move upwind. - Alert Fire Brigade and tell them location and nature of hazard. - Wear full body protective clothing with breathing apparatus. - Prevent, by any means available, spillage from entering drains or water course. - Stop leak if safe to do so. - Contain spill with sand, earth or vermiculite. - Collect recoverable product into labelled containers for recycling. - Neutralise/decontaminate residue (see Section 13 for specific agent). - Collect solid residues and seal in labelled drums for disposal. - Wash area and prevent runoff into drains. - After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using. - If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling

Safe handling	DO NOT allow clothing wet with material to stay in contact with skin - Avoid skin contact, including inhalation. - Wear protective clothing when risk of exposure occurs. - Use in a well-ventilated area. - Prevent concentration in hollows and sumps. DO NOT enter confined spaces until atmosphere has been checked. DO NOT allow material to come in direct contact with human skin or eyes. DO NOT allow material to come in contact with exposed food or food contact surfaces. - Suitable PPE must be worn at all times. - Avoid contact with incompatible materials. When handling, DO NOT eat, drink or smoke. - Keep containers securely sealed when not in use. - Avoid physical damage to containers. - Always wash hands with soap and water after handling. - Work clothes should be laundered separately. Launder contaminated clothing before re-use. - Use good occupational work practice. - Observe manufacturer's storage and handling recommendations contained within this SDS. - Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.
Other information	Consider storage under inert gas. - Store in original containers. - Keep containers securely sealed. - No smoking, naked lights or ignition sources. - Store in a cool, dry, well-ventilated area. - Store away from incompatible materials and foodstuff containers. - Protect containers against physical damage and check regularly for leaks. - Observe manufacturer's storage and handling recommendations contained within this SDS.

Conditions for safe storage, including any incompatibilities

Suitable container	- Glass container is suitable for laboratory quantities - Lined metal can, lined metal pail/ can. - Plastic pail. - Polyliner drum. - Packing as recommended by manufacturer. - Check all containers are clearly labelled and free from leaks. For low viscosity materials - Drums and jerricans must be of the non-removable head type. - Where a can is to be used as an inner package, the can must have a screwed enclosure. For materials with a viscosity of at least 2680 cSt. (23 deg. C) and solids (between 15 C deg. and 40 deg C.): - Removable head packaging; - Cans with friction closures and - low pressure tubes and cartridges may be used. - Where combination packages are used, and the inner packages are of glass, there must be sufficient inert cushioning material in contact with inner and outer packages *. - In addition, where inner packagings are glass and contain liquids of packing group I and II there must be sufficient inert absorbent to absorb any spillage *. - * unless the outer packaging is a close fitting moulded plastic box and the substances are not incompatible with the plastic.
--------------------	---

Storage incompatibility	Avoid reaction with oxidising agents
-------------------------	--------------------------------------

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure Standards	N-methyl-2-pyrrolidone	1-Methyl-2-pyrrolidone	25 ppm / 103 mg/m3	309 mg/m3 / 75 ppm	Not Available	Not Available
Australia Workplace exposure limits for airborne contaminants (WEL list) (Effective from 1 December 2026) - Appendix A - Workplace Exposure Limits	N-methyl-2-pyrrolidone	1-Methyl-2-pyrrolidone	20 ppm / 80 mg/m3	Not Available	Not Available	Not Available

MATERIAL DATA

Exposure controls

Appropriate engineering controls	For potent pharmacological agents: Solutions Handling: - Solutions can be handled outside a containment system or without local exhaust ventilation during procedures with no potential for aerosolisation. If the procedures have a potential for aerosolisation, an air-purifying respirator is to be worn by all personnel in the immediate area. - Solutions used for procedures where aerosolisation may occur (e.g., vortexing, pumping) are to be handled within a containment system or with local exhaust ventilation. - In situations where this is not feasible (may include animal dosing), an air-purifying respirator is to be worn by all personnel in the immediate area. If using a ventilated enclosure that has not been validated, wear a half-mask respirator equipped with HEPA cartridges until the enclosure is validated for use. - Ensure gloves are protective against solvents in use. Unless written procedures, specific to the workplace are available, the following is intended as a guide: For Laboratory-scale handling of Substances assessed to be toxic by inhalation. Quantities of up to 25 grams may be handled in Class II biological safety cabinets*; Quantities of 25 grams to 1 kilogram may be handled in Class II biological safety cabinets* or equivalent containment systems; Quantities exceeding 1 kg may be handled either using specific containment, a hood or Class II biological safety cabinet*. - HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapours. - The need for respiratory protection should also be assessed where incidental or accidental exposure is anticipated. Dependent on levels of contamination, PAPR, full face air purifying devices with P2 or P3 filters or air supplied respirators should be evaluated. When handling: Quantities of up to 25 grams, an approved respirator with HEPA filters or cartridges should be considered; Quantities of 25 grams to 1 kilogram, a half-face negative pressure, full negative pressure, or powered helmet-type air purifying respirator should be considered. Quantities in excess of 1 kilogram, a full face negative pressure, helmet-type air purifying, or supplied air respirator should be considered. Written procedures, specific to a particular work-place, may replace these recommendations * For Class II Biological Safety Cabinets, Types B2 or B3 should be considered. Where only Class I, open fronted Cabinets are available, glove panels may be added, Laminar flow cabinets do not provide sufficient protection when handling these materials unless especially designed to do so. Pilot Plant and Production - Wear appropriate gloves; lab coat, nylon coveralls or disposable Tyvek suit; safety glasses, safety shoes, and disposable booties. Use good manufacturing practices (i.e., cGMPs). - Protective garment (coveralls, Tyvek, lab coat) is not to be worn outside the work area. - Clean/dirty/decontamination areas are to be established. - Negative/positive air pressure relationships and buffer zones required (i.e., ante-room/degowning room/airlock). - Area access is to be restricted. - High-energy operations such as milling, particle sizing, spraying or fluidising should be done within an approved emission control or containment system. - Develop cleaning procedures and techniques that limit potential exposure
Individual protection measures, such as personal protective equipment	
Eye and face protection	- Safety glasses with side shields. - Chemical goggles.[AS/NZS 1337.1, EN166 or national equivalent] - Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].
Skin protection	See Hand protection below
Hands/feet protection	- Wear chemical protective gloves, e.g. PVC. - Wear safety footwear or safety gumboots, e.g. Rubber The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application. The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final choice. Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended. Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: - frequency and duration of contact, - chemical resistance of glove material, - glove thickness and - dexterity

Titan Abamectin 18 (Titan Abamectin 18 Insecticide / Miticide)

	Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent). - When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended. - When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended. - Some glove polymer types are less affected by movement and this should be taken into account when considering gloves for long-term use. - Contaminated gloves should be replaced. As defined in ASTM F-739-96 in any application, gloves are rated as: - Excellent when breakthrough time > 480 min - Good when breakthrough time > 20 min - Fair when breakthrough time < 20 min - Poor when glove material degrades For general applications, gloves with a thickness typically greater than 0.35 mm, are recommended. It should be emphasised that glove thickness is not necessarily a good predictor of glove resistance to a specific chemical, as the permeation efficiency of the glove will be dependent on the exact composition of the glove material. Therefore, glove selection should also be based on consideration of the task requirements and knowledge of breakthrough times. Glove thickness may also vary depending on the glove manufacturer, the glove type and the glove model. Therefore, the manufacturers technical data should always be taken into account to ensure selection of the most appropriate glove for the task. Note: Depending on the activity being conducted, gloves of varying thickness may be required for specific tasks. For example: - Thinner gloves (down to 0.1 mm or less) may be required where a high degree of manual dexterity is needed. However, these gloves are only likely to give short duration protection and would normally be just for single use applications, then disposed of. - Thicker gloves (up to 3 mm or more) may be required where there is a mechanical (as well as a chemical) risk i.e. where there is abrasion or puncture potential Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.
Body protection	See Other protection below
Other protection	- Overalls. - Eyewash unit. - Barrier cream. - Skin cleansing cream.

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the: **"Forsberg Clothing Performance Index"**.
The effect(s) of the following substance(s) are taken into account in the **computer-generated** selection:
Titan Abamectin 18 (Titan Abamectin 18 Insecticide / Miticide)

Material	CPI
BUTYL	A
PE/EVAL/PE	A
NATURAL RUBBER	B
PVA	B

* CPI - Chemwatch Performance Index
A: Best Selection
B: Satisfactory; may degrade after 4 hours continuous immersion
C: Poor to Dangerous Choice for other than short term immersion
NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -
* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Ansell Glove Selection

Glove — In order of recommendation
MICROFLEX® 93-260
AlphaTec® 38-612
AlphaTec® 53-001
AlphaTec® 58-005
AlphaTec® Solvex® 37-175
BioClean™ Fusion (Sterile) S-BFAP
MICROFLEX® Diamond Grip® MF-300
MICROFLEX® LifeStar EC™ 93-868
MICROFLEX® SafeGrip™ SG-375
BioClean™ Emerald BENS

The suggested gloves for use should be confirmed with the glove supplier.

Respiratory protection

Type AK Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required.
Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	AK-AUS	-	AK-PAPR-AUS / Class 1
up to 50 x ES	-	AK-AUS / Class 1	-
up to 100 x ES	-	AK-2	AK-PAPR-2 ^

^ - Full-face
A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
- Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

Appearance	Colourless clear liquid with characteristic odour; mixes with water.		
Physical state	Liquid	Relative density (Water = 1)	1.01
Odour	Characteristic	Partition coefficient n-octanol / water	Not Available

Titan Abamectin 18 (Titan Abamectin 18 Insecticide / Miticide)

Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Available	Decomposition temperature (°C)	Not Available
Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	~70	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Applicable	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Available	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available
Solubility in water	Miscible	pH as a solution (1%)	Not Available
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available
Heat of Combustion (kJ/g)	Not Available	Ignition Distance (cm)	Not Available
Flame Height (cm)	Not Available	Flame Duration (s)	Not Available
Enclosed Space Ignition Time Equivalent (s/m3)	Not Available	Enclosed Space Ignition Deflagration Density (g/m3)	Not Available

SECTION 10 Stability and reactivity

Reactivity	See section 7
Chemical stability	▶ Unstable in the presence of incompatible materials. ▶ Product is considered stable. ▶ Hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 Toxicological information

Information on toxicological effects

a) Acute Toxicity	There is sufficient evidence to classify this material as acutely toxic.
b) Skin Irritation/Corrosion	There is sufficient evidence to classify this material as skin corrosive or irritating.
c) Serious Eye Damage/Irritation	There is sufficient evidence to classify this material as eye damaging or irritating
d) Respiratory or Skin sensitisation	Based on available data, the classification criteria are not met.
e) Mutagenicity	Based on available data, the classification criteria are not met.
f) Carcinogenicity	Based on available data, the classification criteria are not met.
g) Reproductivity	There is sufficient evidence to classify this material as toxic to reproductivity
h) STOT - Single Exposure	There is sufficient evidence to classify this material as toxic to specific organs through single exposure
i) STOT - Repeated Exposure	There is sufficient evidence to classify this material as toxic to specific organs through repeated exposure
j) Aspiration Hazard	Based on available data, the classification criteria are not met.

Inhaled	Inhalation of vapours or aerosols (mists, fumes), generated by the material during the course of normal handling, may produce toxic effects. Evidence shows, or practical experience predicts, that the material produces irritation of the respiratory system, in a substantial number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system. Inhalation of vapours may cause drowsiness and dizziness. This may be accompanied by narcosis, reduced alertness, loss of reflexes, lack of coordination and vertigo. Inhalation of high vapour concentrations of N-methyl-2-pyrrolidone (NMP) may produce mucous membrane irritation, headache, giddiness, mental confusion and nausea. Fatalities were not recorded following inhalation of 180-200 mg/m3 for 2 hours by mice and following a 6 hour exposure to saturated vapours by rats. Laboratory animals exposed to concentrations of 50 ppm for 8 hours daily for 20 days or 370 ppm for 6 hours daily for 10 days showed no gross or histopathological abnormalities
Ingestion	Severely toxic effects may result from the accidental ingestion of the material; animal experiments indicate that ingestion of less than 5 gram may be fatal or may produce serious damage to the health of the individual. Macrolides comprise a large group of antibiotics derived from <i>Streptomyces spp.</i> and other microbial and plant species, having in common a macrocyclic lactone ring to which one or more sugars are attached. They are all weak bases. The most common side effect produced by the family of macrolide antibiotics is gastrointestinal discomfort. Supra-infections may occur although these are rare. Several macrolides produced allergic sensitisation but, again, these are rare. Symptoms include watery eyes, shortness of breath, nasal congestion, choking, coughing and wheezing. Allergic skin reactions have also occurred. Exposure to at least one member of the family, erythromycin, at high concentrations, has produced reversible deafness (ototoxicity). Systemic reactions including fever, rash, and lymph-node pain or swelling have been produced by the avermectin group. Ivermectin has produced ataxia (incoordination), lethargy, bradypnea (slowed breathing), vomiting, mydriasis (dilated pupils), sedation, tremors and death in animals. The avermectin group (anthelmintics, insecticides and

Titan Abamectin 18 (Titan Abamectin 18 Insecticide / Miticide)

	acaricides) mediate the transmission of gamma-butyric acid (GABA), an inhibitory neurotransmitter, in mammals thus causing paralysis. Hepatotoxic effects with transient disturbances and jaundice have resulted from the use of oleandomycin. Transient alterations in heart rate/rhythm have also been produced by several members of the family (notably tilimicosin). Heart muscle degeneration, characterised by small areas of cell death have also been reported in animals exposed to tilimicosin. Cross-resistance is often observed between the macrolide, lincosamide and streptogramin group of antibiotics. Macrolides should not be taken with colchicine as it may lead to colchicine toxicity. Symptoms of colchicine toxicity include gastrointestinal upset, fever, myalgia, pancytopenia, and organ failure The combination of some macrolides and statins (used for lowering cholesterol) is not advisable and can lead to debilitating myopathy. This is because some macrolides (clarithromycin and erythromycin, not azithromycin) are potent inhibitors of the cytochrome P450 system, particularly of CYP3A4. Macrolides, mainly erythromycin and clarithromycin, also have a class effect of QT prolongation, which can lead to torsades de pointes. Macrolides exhibit enterohepatic recycling; that is, the drug is absorbed in the gut and sent to the liver, only to be excreted into the duodenum in bile from the liver. This can lead to a buildup of the product in the system, thereby causing nausea. In infants the use of erythromycin has been associated with pyloric stenosis. Some macrolides are also known to cause cholestasis, a condition where bile cannot flow from the liver to the duodenum. One study found an association between erythromycin use during infancy and developing (infantile hypertrophic pyloric stenosis.(IHPS - which can progress to near-complete obstruction of the gastric outlet, leading to forceful vomiting in infants) . However, no significant association was found between macrolides use during pregnancy or breastfeeding Considered an unlikely route of entry in commercial/industrial environments The liquid may produce considerable gastrointestinal discomfort and may be harmful or toxic if swallowed. Ingestion may result in nausea, pain and vomiting. Vomit entering the lungs by aspiration may cause potentially lethal chemical pneumonitis												
Skin Contact	Evidence exists, or practical experience predicts, that the material either produces inflammation of the skin in a substantial number of individuals following direct contact, and/or produces significant inflammation when applied to the healthy intact skin of animals, for up to four hours, such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis. The material may accentuate any pre-existing dermatitis condition Skin contact with the material may damage the health of the individual; systemic effects may result following absorption. Prolonged contact with N-methyl-2-pyrrolidone (NMP) reportedly causes severe dermatitis with redness, cracking, swelling, blisters and oedema. An instance of severe skin irritation after a few days work with NMP shows latex rubber gloves as giving insufficient protection. A review article casts doubts on reliability of animal single patch tests, i.e Draize tests. [Irritant Cutaneous Reaction to NMP, Contact Dermatitis 27: 148-150, 1992] Absorption by skin may readily exceed vapour inhalation exposure. Symptoms for skin absorption are the same as for inhalation.												
Eye	Direct contact with the liquid N-methyl-2-pyrrolidone (NMP) may produce painful burning or stinging of the eyes and lids, watering and inflammation of the conjunctiva and temporary corneal clouding. Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Repeated or prolonged eye contact may cause inflammation characterised by a temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.												
Chronic	Long-term exposure to respiratory irritants may result in disease of the airways involving difficult breathing and related systemic problems. Toxic: danger of serious damage to health by prolonged exposure through inhalation, in contact with skin and if swallowed. Serious damage (clear functional disturbance or morphological change which may have toxicological significance) is likely to be caused by repeated or prolonged exposure. As a rule the material produces, or contains a substance which produces severe lesions. Such damage may become apparent following direct application in subchronic (90 day) toxicity studies or following sub-acute (28 day) or chronic (two-year) toxicity tests. There is sufficient evidence to establish a causal relationship between human exposure to the material and impaired fertility There is sufficient evidence to establish a causal relationship between human exposure to the material and subsequent developmental toxic effects in the off-spring. There is sufficient evidence to provide a strong presumption that human exposure to the material may result in impaired fertility on the basis of: - clear evidence in animal studies of impaired fertility in the absence of toxic effects, or evidence of impaired fertility occurring at around the same dose levels as other toxic effects but which is not a secondary non-specific consequence of other toxic effects. There is sufficient evidence to provide a strong presumption that human exposure to the material may result in developmental toxicity, generally on the basis of: - clear results in appropriate animal studies where effects have been observed in the absence of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not secondary non-specific consequences of the other toxic effects. Exposure to the material may cause concerns for humans owing to possible developmental toxic effects, generally on the basis that results in appropriate animal studies provide strong suspicion of developmental toxicity in the absence of signs of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not a secondary non-specific consequence of other toxic effects. Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems. The teratogenic potential, subchronic and long term inhalation toxicity of N-methyl-2-pyrrolidone (NMP) has been studied in rats. No evidence of nephrotoxicity was seen. No carcinogenic effects were observed. Very high doses are embryotoxic to rats and mice. Reproductive effects have been reported in animals.												
Titan Abamectin 18 (Titan Abamectin 18 Insecticide / Miticide)	<table> <tr> <th>TOXICITY</th><th>IRRITATION</th></tr> <tr> <td>Not Available</td><td>Not Available</td></tr> </table>	TOXICITY	IRRITATION	Not Available	Not Available								
TOXICITY	IRRITATION												
Not Available	Not Available												
N-methyl-2-pyrrolidone	<table> <tr> <th>TOXICITY</th><th>IRRITATION</th></tr> <tr> <td>Dermal (rabbit) LD50: 8000 mg/kg^[2]</td><td>Eye (Human): 530ppm/30M - Mild</td></tr> <tr> <td>Inhalation (Rat) LC50: 3.1-8.8 mg/l4h^[2]</td><td>Eye (Rodent - rabbit): 0.1mL</td></tr> <tr> <td>Oral (Rat) LD50: 3914 mg/kg^[2]</td><td>Eye (Rodent - rabbit): 100mg - Moderate</td></tr> <tr> <td></td><td>Eye: adverse effect observed (irritating)^[1]</td></tr> <tr> <td></td><td>Skin: adverse effect observed (irritating)^[1]</td></tr> </table>	TOXICITY	IRRITATION	Dermal (rabbit) LD50: 8000 mg/kg ^[2]	Eye (Human): 530ppm/30M - Mild	Inhalation (Rat) LC50: 3.1-8.8 mg/l4h ^[2]	Eye (Rodent - rabbit): 0.1mL	Oral (Rat) LD50: 3914 mg/kg ^[2]	Eye (Rodent - rabbit): 100mg - Moderate		Eye: adverse effect observed (irritating) ^[1]		Skin: adverse effect observed (irritating) ^[1]
TOXICITY	IRRITATION												
Dermal (rabbit) LD50: 8000 mg/kg ^[2]	Eye (Human): 530ppm/30M - Mild												
Inhalation (Rat) LC50: 3.1-8.8 mg/l4h ^[2]	Eye (Rodent - rabbit): 0.1mL												
Oral (Rat) LD50: 3914 mg/kg ^[2]	Eye (Rodent - rabbit): 100mg - Moderate												
	Eye: adverse effect observed (irritating) ^[1]												
	Skin: adverse effect observed (irritating) ^[1]												

Titan Abamectin 18 (Titan Abamectin 18 Insecticide / Miticide)

abamectin	TOXICITY	IRRITATION
	dermal (rat) LD50: >330 mg/kg ^[2]	Not Available
	Inhalation (Rat) LC50: 1.1 mg/L4h ^[2]	
	Oral (Mouse) LD50; 13.6 mg/kg ^[2]	

Legend:

1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2. Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances

N-METHYL-2-PYRROLIDONE

Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production.

for N-methyl-2-pyrrolidone (NMP):

Acute toxicity: In rats, NMP is absorbed rapidly after inhalation, oral, and dermal administration, distributed throughout the organism, and eliminated mainly by hydroxylation to polar compounds, which are excreted via urine. About 80% of the administered dose is excreted as NMP and NMP metabolites within 24 h. A probably dose-dependent yellow coloration of the urine in rodents is observed. The major metabolite is 5-hydroxy-*N*-methyl-2-pyrrolidone.

Studies in humans show comparable results. Dermal penetration through human skin has been shown to be very rapid. NMP is rapidly biotransformed by hydroxylation to 5-hydroxy-*N*-methyl-2-pyrrolidone, which is further oxidized to *N*-methylsuccinimide; this intermediate is further hydroxylated to 2-hydroxy-*N*-methylsuccinimide. These metabolites are all colourless. The excreted amounts of NMP metabolites in the urine after inhalation or oral intake represented about 100% and 65% of the administered doses, respectively.

NMP has a low potential for skin irritation and a moderate potential for eye irritation in rabbits. Repeated daily doses of 450 mg/kg body weight administered to the skin caused painful and severe haemorrhage and eschar formation in rabbits. These adverse effects have not been seen in workers occupationally exposed to pure NMP, but they have been observed after dermal exposure to NMP used in cleaning processes. No sensitisation potential has been observed.

In acute toxicity studies in rodents, NMP showed low toxicity. Uptake of oral, dermal, or inhaled acutely toxic doses causes functional disturbances and depressions in the central nervous system. Local irritation effects were observed in the respiratory tract when NMP was inhaled and in the pyloric and gastrointestinal tracts after oral administration. In humans, there was no irritative effect in the respiratory system after an 8-h exposure to 50 mg/m³.

Repeat dose toxicity: There is no clear toxicity profile of NMP after multiple administration. In a 28-day dietary study in rats, a compound-related decrease in body weight gain was observed in males at 1234 mg/kg body weight and in females at 2268 mg/kg body weight.

Testicular degeneration and atrophy in males and thymic atrophy in females were observed at these dose levels. The no-observed-adverse-effect level (NOAEL) was 429 mg/kg body weight in males and 1548 mg/kg body weight in females. In a 28-day intubation study in rats, a dose-dependent increase in relative liver and kidney weights and a decrease in lymphocyte count in both sexes were observed at 1028 mg/kg body weight. The NOAEL in this study was 514 mg/kg body weight. In another rat study, daily dietary intake for 90 days caused decreased body weights at doses of 433 and 565 mg/kg body weight in males and females, respectively. There were also neurobehavioural effects at these dose levels. The NOAELs in males and females were 169 and 217 mg/kg body weight, respectively.

The toxicity profile after exposure to airborne NMP depends strongly on the ratio of vapour to aerosol and on the area of exposure (i.e., head-only or whole-body exposure). Because of higher skin absorption for the aerosol, uptake is higher in animals exposed to aerosol than in those exposed to vapour at similar concentrations. Studies in female rats exposed head only to 1000 mg/m³ showed only minor nasal irritation, but massive mortality and severe effects on major organs were observed when the females were whole-body exposed to the same concentration of coarse droplets at high relative humidity. Several studies in rats following repeated exposure to NMP at concentrations between 100 and 1000 mg/m³ have shown systemic toxicity effects at the lower dose levels. In most of the studies, the effects were not observed after a 4-week observation period.

In rats, exposure to 3000 mg NMP/m³ (head only) for 6 h/day, 5 days/week, for 13 weeks caused a decrease in body weight gain, an increase in erythrocytes, haemoglobin, haematocrit, and mean corpuscular volume, decreased absolute testis weight, and cell loss in the germinal epithelium of the testes. The NOAEL was 500 mg/m³.

There are no data in humans after repeated-dose exposure.

Carcinogenicity: NMP did not show any clear evidence for carcinogenicity in rats exposed to concentrations up to 400 mg/m³ in a long-term inhalation study.

Genotoxicity: The mutagenic potential of NMP is weak. Only a slight increase in the number of revertants was observed when tested in a *Salmonella* assay with base-pair substitution strains. NMP has been shown to induce aneuploidy in yeast *Saccharomyces cerevisiae* cells. No investigations regarding mutagenicity in humans were available.

Reproductive toxicity: In a two-generation reproduction study in rats, whole-body exposure of both males and females to 478 mg/m³ of NMP vapour for 6 h/day, 7 days/week, for a minimum of 100 days (pre-mating, mating, gestation, and lactation periods) resulted in a 7% decrease in fetal weight in the F1 offspring. A 4-11% transient, non-dose-dependent decrease was observed in the average pup weight at all exposure levels tested (41, 206, and 478 mg/m³).

Developmental toxicity: When NMP was administered dermally, developmental toxicity was registered in rats at 750 mg/kg body weight. The observed effects were increased preimplantation losses, decreased fetal weights, and delayed ossification. The NOAEL for both developmental effects and maternal toxicity (decreased body weight gain) was 237 mg/kg body weight.

Inhalation studies in rats (whole-body exposure) demonstrated developmental toxicity as increased preimplantation loss without significant effect on implantation rate or number of live fetuses at 680 mg/m³ and behavioural developmental toxicity at 622 mg/m³. In an inhalation study (whole-body exposure), the NOAEL for maternal effects was 100 mg/m³, and the NOAEL for developmental effects was 360 mg/m³.

A tolerable inhalation concentration, 0.3 mg/m³, based on mortality and organ damage, is expected to be protective against any possible reproductive toxicity. Similarly, an oral tolerable intake of 0.6 mg/kg body weight per day, based on a 90-day study, is expected to provide adequate protection against possible reproductive effects. Because of non-existent data on the exposure of the general population and very limited information on occupational exposure, no meaningful risk characterisation can be performed.

A substance (or part of a group of chemical substances) of very high concern (SVHC) - or product containing an SVHC:

It is proposed that use within the European Union be subject to authorisation under the REACH Regulation. Indeed, listing of a substance as an SVHC by the European Chemicals Agency (ECHA) is the first step in the procedure for authorisation or restriction of use of a chemical.

The criteria are given in article 57 of the REACH Regulation. A substance may be proposed as an SVHC if it meets one or more of the following criteria:

- ▶ it is carcinogenic *;
- ▶ it is mutagenic *;
- ▶ it is toxic for reproduction *;
- ▶ it is persistent, bioaccumulative and toxic (PBT substances);
- ▶ it is very persistent and very bioaccumulative (vPvB substances);
- ▶ there is "scientific evidence of probable serious effects to human health or the environment which give rise to an equivalent level of concern"; such substances are identified on a case-by-case basis.

* Collectively described as CMR substances

The "equivalent concern" criterion is significant because it is this classification which allows substances which are, for example, neurotoxic, endocrine-disrupting or otherwise present an unanticipated environmental health risk to be regulated under REACH]

Continued...

Titan Abamectin 18 (Titan Abamectin 18 Insecticide / Miticide)

	Simply because a substance meets one or more of the criteria does not necessarily mean that it will be proposed as an SVHC. Many such substances are already subject to restrictions on their use within the European Union, such as those in Annex XVII of the REACH Regulation. SVHCs are substances for which the current restrictions on use (where these exist) might be insufficient. There are three priority groups for assessment: ▶ PBT substances and vPvB substances; ▶ substances which are widely dispersed during use; ▶ substances which are used in large quantities.
ABAMECTIN	Oral (rat) LD50: 8.7-12.8 mg/kg (14 day) * ADI 0.0001 mg/kg Toxicity Class EPA IV Non-mutagenic in the Ames test ADI: 0.4 mg/day * [Manufacturer] Convulsions recorded. No significant acute toxicological data identified in literature search. For avermectins: Technical avermectin exhibits high mammalian acute toxicity. In vertebrates, the effects occur via poisoning of the central nervous system (CNS) through reactions at the receptor for the inhibitory neurotransmitter GABA. The avermectins open the GABAA receptor chloride channel by binding to the GABA recognition site (receptor protein) and act as partial agonists.. Chloride ions then flow into the postsynaptic neuron. This chloride permeability increase can significantly hyperpolarize (make more negative) the membrane potential, which has a dampening effect on nerve impulse firing. There is also a reversible dose-dependent increase in chloride ion permeability in response to very low doses of avermectins. In GABA-insensitive neurons with no inhibitory innervation, the avermectins induce an irreversible increase in chloride ion conductance through interacting with voltage-dependent chloride channels. Avermectin intoxication in mammals begins with hyperexcitability, tremors, and incoordination and later develops into ataxia and coma-like sedation. This is similar to the mode of action of ethanol and barbiturates and benzodiazepine sedatives. However, the avermectins are less specific in their action and can affect a variety of other ligand- and voltage-gated chloride channels. The general safety of the avermectins depends on the presence of an intact P-glycoprotein blood-brain barrier. Avermectin is not considered to be mutagenic and does not sensitize skin. It is not readily absorbed by mammals and the majority of the residue is excreted in the faeces within 2 days. The 24-month rat chronic feeding/ oncogenicity study and 94-week mouse chronic toxicity oncogenicity study were negative for oncogenic potential. The results of a series of developmental toxicity studies (rat, rabbit, mouse) have been evaluated and showed that avermectin B1 produces developmental toxicity (cleft palate) in the CF1 mouse. Toxicology data were also evaluated for the delta-8,9-isomer of avermectin B1 which is a plant photodegradate that can range between 5 and 20 percent of the residue on/in cottonseed. This isomer possesses avermectin-like toxicological activity. It was concluded that the delta 8,9-isomer also produces developmental toxicity (cleft palate) in mice, but not in rats. In addition to avermectin and its delta 8,9-isomer, toxicology data were also evaluated for the "polar degradates" of avermectin, which constitute a large percentage (up to 70%) of the total residue on cottonseed. Review of the toxicology data indicated that these polar degradates do not possess avermectin-like toxicological activity and for this reason need not be included in the tolerance expression for residues in/on cottonseed. Abamectin (a mixture of avermectin isomers) is a reproductive toxin in laboratory animals at doses which are acutely toxic to the mother. In development toxicity studies with abamectin, cleft palates were seen in mice and rabbits and clubbing of the forepaws was seen in rabbits. The no-observed-adverse-effect-level (NOAEL) for maternal and developmental toxicity in rabbits was 1 mg/kg/day. In CF-1 mice, a strain recognised to be particularly sensitive to avermectins, the NOAEL for maternal toxicity was 0.05 mg/kg/day and the NOAEL for malformations was 0.2 mg/kg/day. Studies show that the sensitivity of a subpopulation of CF-1 mice to avermectins is due to the absence of a transmembrane P-glycoprotein, a significant component of the blood-brain interface that normally acts as a non-selective protective barrier in a wide range of species including humans. CF-1 mice are therefore an unlikely candidate for assessing human risk. No evidence of developmental toxicity was seen in oral studies in rats in the absence of maternal toxicity (NOAEL = 1.6 mg/kg/day). In a rat multigenerational reproduction study, pup toxicity and deaths were seen at 0.4 mg/kg/day (NOAEL = 0.12 mg/kg/day). Neonatal rats are not an appropriate model for assessing human risk in humans because (a) rat milk has a greater fat content than human breast milk and abamectin concentrates in fat; (b) on a weight basis, the neonatal rat consumes significantly greater quantities of milk than the newborn human and(c) the blood brain barrier in rodents is formed post-natally (as evidenced by low P-glycoprotein levels) while in humans this membrane is formed pre-natally. Ivermectin, a close structural analogue, has been used extensively in the treatment of human onchocerciasis at an oral therapeutic dose of 0.2 mg/kg, without serious drug-related effects. Despite its wide usage in animals and humans, ivermectin does not appear to produce birth defects. Abamectin is non-mutagenic in the Ames test and the micronucleus test. Dietary carcinogenicity studies in mice and rats showed negative results. In a 14-week oral study in monkeys no effects were seen at 0.2, 0.5 or 1.0 mg/kg/day; emesis was seen at 2.0 mg/kg/day; delayed pupillary obstruction at 6 and 8 mg/kg/day and mydriasis at 12 mg/kg/day. In chronic oral toxicity, abamectin produced decreased body weight gain in mice (no-observed-adverse-effect-level (NOAEL) = 1.5 mg/kg/day); tremors in rats (NOAEL = 1.5 mg/kg/day), weight loss, tremors, mydriasis, liver and gall bladder changes and death in dogs (NOAEL = 0.25 mg/kg/day); and emesis, mydriasis and sedation in monkeys (NOAL = 1 mg/kg/day).

Acute Toxicity	✓	Carcinogenicity	✗
Skin Irritation/Corrosion	✓	Reproductivity	✓
Serious Eye Damage/Irritation	✓	STOT - Single Exposure	✓
Respiratory or Skin sensitisation	✗	STOT - Repeated Exposure	✓
Mutagenicity	✗	Aspiration Hazard	✗

Legend: ✗ – Data either not available or does not fill the criteria for classification
✓ – Data available to make classification

SECTION 12 Ecological information

Toxicity					
Titan Abamectin 18 (Titan Abamectin 18 Insecticide / Miticide)	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Available
N-methyl-2-pyrrolidone	Endpoint	Test Duration (hr)	Species	Value	Source
	EC50	72h	Algae or other aquatic plants	>500mg/l	1
	EC50	48h	Crustacea	ca.4897mg/l	1
	LC50	96h	Fish	464mg/l	1
	NOEC(ECx)	504h	Crustacea	12.5mg/l	2

Titan Abamectin 18 (Titan Abamectin 18 Insecticide / Miticide)

abamectin	Endpoint	Test Duration (hr)	Species	Value	Source
	EC50	72h	Algae or other aquatic plants	4.4mg/l	4
	EC50	48h	Crustacea	<0.001mg/L	4
	EC50(ECx)	48h	Crustacea	<0.001mg/L	4
	EC50	96h	Algae or other aquatic plants	7.31mg/l	4
	LC50	96h	Fish	0.002-0.006mg/L	4
Legend: <i>Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 3. US EPA, Ecotox database - Aquatic Toxicity Data 4. ECETOC Aquatic Hazard Assessment Data 5. NITE (Japan) - Bioconcentration Data 6. METI (Japan) - Bioconcentration Data 7. Vendor Data</i>					

Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Do NOT allow product to come in contact with surface waters or to intertidal areas below the mean high water mark. Do not contaminate water when cleaning equipment or disposing of equipment wash-waters.

Wastes resulting from use of the product must be disposed of on site or at approved waste sites.

Toxic to bees.

For macrocyclic lactones (MLs) antibiotics and insecticides, typically avermectins (including ivermectins), milbemycins and spinosyns.

The environmental impacts of many macrocyclic lactones make them substances of high concern particularly with larval instars of invertebrates. Studies have also shown that susceptibility varies with life cycle stage and impacts can be mitigated by using MLs when these stages are not present.

The physical/chemical properties of MLs indicate that, once they have entered the environment, they can persist for extended periods of time at concentrations high enough to exert toxic impacts. To date, pasture ecosystems have been of greatest concern. In terrestrial systems, the entry of MLs into the environment is through livestock excretion on pasture soils. MLs enter marine systems in the faeces of farmed salmon, as well as through uneaten food that settles in sediments

MLs may enter the terrestrial compartment via spreading of manure from intensively reared animals on arable land or by excretion of dung by animals on pastures. Several models were developed to estimate the environmental burden (predicted environmental concentration, PEC) of MLs that accumulates in environment, both in the terrestrial and aquatic environment Ivermectin was selected as a case study compound within the project ERAPharm (Environmental Risk Assessment of Pharmaceuticals) The ERA clearly demonstrated unacceptable risks for all investigated environmental compartments and hence suggested the necessity of reassessing ivermectin-containing products. Based on this case study, several gaps in the existing guidelines for ERA of pharmaceuticals were shown and improvements have been suggested]. The risk characterization using long-term effects data for aquatic and sediment organisms (D. magna and C. riparius) as required according to VICH 2004 resulted in an indication of risk for these compartments. While the Risk quotient (RQ) for sediment organisms was between 2.1 and 36, the RQ for daphnids was >105, indicating a very high risk for aquatic invertebrates

for N-methyl-2-pyrrolidinone (NMP):

log Kow : -0.44-0.1

Environmental Fate

NMP may enter the environment as emissions to the atmosphere, as the substance is volatile and widely used as a solvent, or it may be released to water as a component of municipal and industrial wastewaters. The substance is mobile in soil, and leaching from landfills is thus a possible route of contamination of groundwater.

In air, NMP is expected to be removed by wet deposition or by photochemical reactions with hydroxyl radicals. As the substance is completely miscible in water, it is not expected to adsorb to soil, sediments, or suspended organic matter or to bioconcentrate. NMP is not degraded by chemical hydrolysis. Data from screening tests on the biodegradability of NMP show that the substance is rapidly biodegraded.

This material is not expected to persist in the environment. It is water soluble and is expected to have low volatility. Hydrolysis is not expected to be an important factor in the environmental fate process for this material.

Persistence and Degradability

Biodegradation: BOD (Modified MITI Method) = 73% (28 days). BOD (Modified MITI Method) = 92% (14 days). This material is expected to be readily biodegradable.

Bioaccumulation: BCF = 0.16. This material is not expected to bioaccumulate

Ecotoxicity

This material is expected to be non-hazardous to aquatic species.

Fish LC50 (96 h): bluegill. 832 mg/l, fathead minnow 1072 mg/l; rainbow trout 3048 mg/l

Daphnia magna EC50 (24 h): > 1000 mg/l

Algae EC50 (72 h): Scenedesmus subspicatus > 500 mg/l

Risk Quotient (RQ) =Exposure/Toxicity where

- Exposure refers to estimated environmental concentration (EEC).
- Toxicity refers to an effect level or endpoint obtained from eco-toxicity testing, such as an LC50 or NOEC

After the risk quotient(s) is calculated, it is compared to US EPA's Level of Concern (LOC). If RQ is less than LOC, it is generally regarded that the risk is acceptable.

The table below describes different types of risk quotients for aquatic species and EPA's level of concern. An LOC is a policy tool that the Agency uses to interpret the risk quotient and to analyze potential risk to non-target organisms and the need to consider regulatory action.

Risk Presumptions	Risk Quotient	LOC
Acute High Risk	EEC/ lowest LC50 or EC50	0.5
Acute Restricted Use	EEC/ lowest LC50 or EC50	0.1
Acute Endangered Species	EEC/ lowest LC50 or EC50	0.05
Chronic Risk	EEC/ lowest LC50 or EC50	1.0

DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
N-methyl-2-pyrrolidone	LOW	LOW

Bioaccumulative potential

Ingredient	Bioaccumulation
N-methyl-2-pyrrolidone	LOW (BCF = 0.16)
abamectin	MEDIUM (LogKOW = 4.4)

Mobility in soil

Ingredient	Mobility
N-methyl-2-pyrrolidone	LOW (Log KOC = 20.94)

SECTION 13 Disposal considerations

Waste treatment methods

Product / Packaging disposal	▶ Containers may still present a chemical hazard/ danger when empty. ▶ Return to supplier for reuse/ recycling if possible. Otherwise:
------------------------------	--

Titan Abamectin 18 (Titan Abamectin 18 Insecticide / Miticide)

- ▶ If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.
 - ▶ Where possible retain label warnings and SDS and observe all notices pertaining to the product.
- Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked.

A Hierarchy of Controls seems to be common - the user should investigate:

- ▶ Reduction
- ▶ Reuse
- ▶ Recycling
- ▶ Disposal (if all else fails)

This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. If it has been contaminated, it may be possible to reclaim the product by filtration, distillation or some other means. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate.

- ▶ **DO NOT allow wash water from cleaning or process equipment to enter drains.**
- ▶ It may be necessary to collect all wash water for treatment before disposal.
- ▶ In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.
- ▶ Where in doubt contact the responsible authority.
- ▶ Recycle wherever possible or consult manufacturer for recycling options.
- ▶ Consult State Land Waste Authority for disposal.
- ▶ Bury or incinerate residue at an approved site.
- ▶ Recycle containers if possible, or dispose of in an authorised landfill.

SECTION 14 Transport information

Labels Required

	
Marine Pollutant	
HAZCHEM	2X

Land transport (ADG)

14.1. UN number or ID number	2902				
14.2. UN proper shipping name	PESTICIDE, LIQUID, TOXIC, N.O.S. (contains abamectin)				
14.3. Transport hazard class(es)	<table> <tr> <td>Class</td><td>6.1</td></tr> <tr> <td>Subsidiary Hazard</td><td>Not Applicable</td></tr> </table>	Class	6.1	Subsidiary Hazard	Not Applicable
Class	6.1				
Subsidiary Hazard	Not Applicable				
14.4. Packing group	III				
14.5. Environmental hazard	Environmentally hazardous				
14.6. Special precautions for user	<table> <tr> <td>Special provisions</td><td>61 223 274</td></tr> <tr> <td>Limited quantity</td><td>5 L</td></tr> </table>	Special provisions	61 223 274	Limited quantity	5 L
Special provisions	61 223 274				
Limited quantity	5 L				

Air transport (ICAO-IATA / DGR)

14.1. UN number	2902														
14.2. UN proper shipping name	Pesticide, liquid, toxic, n.o.s. * (contains abamectin)														
14.3. Transport hazard class(es)	<table> <tr> <td>ICAO/IATA Class</td><td>6.1</td></tr> <tr> <td>ICAO / IATA Subsidiary Hazard</td><td>Not Applicable</td></tr> <tr> <td>ERG Code</td><td>6L</td></tr> </table>	ICAO/IATA Class	6.1	ICAO / IATA Subsidiary Hazard	Not Applicable	ERG Code	6L								
ICAO/IATA Class	6.1														
ICAO / IATA Subsidiary Hazard	Not Applicable														
ERG Code	6L														
14.4. Packing group	III														
14.5. Environmental hazard	Environmentally hazardous														
14.6. Special precautions for user	<table> <tr> <td>Special provisions</td><td>A3 A4</td></tr> <tr> <td>Cargo Only Packing Instructions</td><td>663</td></tr> <tr> <td>Cargo Only Maximum Qty / Pack</td><td>220 L</td></tr> <tr> <td>Passenger and Cargo Packing Instructions</td><td>655</td></tr> <tr> <td>Passenger and Cargo Maximum Qty / Pack</td><td>60 L</td></tr> <tr> <td>Passenger and Cargo Limited Quantity Packing Instructions</td><td>Y642</td></tr> <tr> <td>Passenger and Cargo Limited Maximum Qty / Pack</td><td>2 L</td></tr> </table>	Special provisions	A3 A4	Cargo Only Packing Instructions	663	Cargo Only Maximum Qty / Pack	220 L	Passenger and Cargo Packing Instructions	655	Passenger and Cargo Maximum Qty / Pack	60 L	Passenger and Cargo Limited Quantity Packing Instructions	Y642	Passenger and Cargo Limited Maximum Qty / Pack	2 L
Special provisions	A3 A4														
Cargo Only Packing Instructions	663														
Cargo Only Maximum Qty / Pack	220 L														
Passenger and Cargo Packing Instructions	655														
Passenger and Cargo Maximum Qty / Pack	60 L														
Passenger and Cargo Limited Quantity Packing Instructions	Y642														
Passenger and Cargo Limited Maximum Qty / Pack	2 L														

Sea transport (IMDG-Code / GGVSee)

14.1. UN number	2902
	PESTICIDE, LIQUID, TOXIC, N.O.S. (contains abamectin)

Continued...

Titan Abamectin 18 (Titan Abamectin 18 Insecticide / Miticide)

14.2. UN proper shipping name		
14.3. Transport hazard class(es)	IMDG Class	6.1
	IMDG Subsidiary Hazard	Not Applicable
14.4. Packing group	III	
14.5 Environmental hazard	Marine Pollutant	
14.6. Special precautions for user	EMS Number	F-A, S-A
	Special provisions	61 223 274
	Limited Quantities	5 L

14.7. Maritime transport in bulk according to IMO instruments

14.7.1. Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

14.7.2. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
N-methyl-2-pyrrolidone	Not Applicable
abamectin	Not Applicable

14.7.3. Transport in bulk in accordance with the IGC Code

Product name	Ship Type
N-methyl-2-pyrrolidone	Not Applicable
abamectin	Not Applicable

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

N-methyl-2-pyrrolidone is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6
Australian Inventory of Industrial Chemicals (AIIC)
Chemical Footprint Project - Chemicals of High Concern List

abamectin is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 4
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 7
Chemical Footprint Project - Chemicals of High Concern List

Additional Regulatory Information

Not Applicable

National Inventory Status

National Inventory	Status
Australia - AIIC / Australia Non-Industrial Use	No (abamectin)
Canada - DSL	No (abamectin)
Canada - NDSL	No (N-methyl-2-pyrrolidone; abamectin)
China - IECSC	No (abamectin)
Europe - EINEC / ELINCS / NLP	No (abamectin)
Japan - ENCS	No (abamectin)
Korea - KECI	Yes
New Zealand - NZIoC	Yes
Philippines - PICCS	No (abamectin)
USA - TSCA	TSCA Inventory 'Active' substance(s) (N-methyl-2-pyrrolidone); No (abamectin)
Taiwan - TCSI	Yes
Mexico - INSQ	Yes
Vietnam - NCI	Yes
Russia - FBEPH	No (abamectin)
UAE - Control List (Banned/Restricted Substances)	No (N-methyl-2-pyrrolidone)

Legend: Yes = All CAS declared ingredients are on the inventory

National Inventory	Status
	No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.

SECTION 16 Other information

Revision Date	30/04/2026
Initial Date	31/12/2025

SDS Version Summary

Version	Date of Update	Sections Updated
2.1	02/01/2026	Toxicological information - Acute Health (eye), Toxicological information - Acute Health (inhaled), Toxicological information - Acute Health (skin), Toxicological information - Acute Health (swallowed), First Aid measures - Advice to Doctor, Physical and chemical properties - Appearance, Toxicological information - Chronic Health, Hazards identification - Classification, Ecological Information - Environmental, Firefighting measures - Fire Fighter (fire/explosion hazard), Firefighting measures - Fire Fighter (fire fighting), First Aid measures - First Aid (eye), First Aid measures - First Aid (skin), Handling and storage - Handling Procedure, Composition / information on ingredients - Ingredients, Accidental release measures - Spills (major), Accidental release measures - Spills (minor), Handling and storage - Storage (storage incompatibility), Handling and storage - Storage (storage requirement), Identification of the substance / mixture and of the company / undertaking - Supplier Information, Identification of the substance / mixture and of the company / undertaking - Synonyms, Transport Information, Name
3.1	30/04/2026	Physical and chemical properties - Appearance

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

- ▶ PC - TWA: Permissible Concentration-Time Weighted Average
- ▶ PC - STEL: Permissible Concentration-Short Term Exposure Limit
- ▶ IARC: International Agency for Research on Cancer
- ▶ ACGIH: American Conference of Governmental Industrial Hygienists
- ▶ STEL: Short Term Exposure Limit
- ▶ TEEL: Temporary Emergency Exposure Limit,
- ▶ IDLH: Immediately Dangerous to Life or Health Concentrations
- ▶ ES: Exposure Standard
- ▶ OSF: Odour Safety Factor
- ▶ NOAEL: No Observed Adverse Effect Level
- ▶ LOAEL: Lowest Observed Adverse Effect Level
- ▶ TLV: Threshold Limit Value
- ▶ LOD: Limit Of Detection
- ▶ OTV: Odour Threshold Value
- ▶ BCF: BioConcentration Factors
- ▶ BEI: Biological Exposure Index
- ▶ DNEL: Derived No-Effect Level
- ▶ PNEC: Predicted no-effect concentration
- ▶ MARPOL: International Convention for the Prevention of Pollution from Ships
- ▶ IMSBC: International Maritime Solid Bulk Cargoes Code
- ▶ IGC: International Gas Carrier Code
- ▶ IBC: International Bulk Chemical Code
- ▶ AIIC: Australian Inventory of Industrial Chemicals
- ▶ DSL: Domestic Substances List
- ▶ NDSL: Non-Domestic Substances List
- ▶ IECSC: Inventory of Existing Chemical Substance in China
- ▶ EINECS: European INventory of Existing Commercial chemical Substances
- ▶ ELINCS: European List of Notified Chemical Substances
- ▶ NLP: No-Longer Polymers
- ▶ ENCS: Existing and New Chemical Substances Inventory
- ▶ KECI: Korea Existing Chemicals Inventory
- ▶ NZIoC: New Zealand Inventory of Chemicals
- ▶ PICCS: Philippine Inventory of Chemicals and Chemical Substances
- ▶ TSCA: Toxic Substances Control Act
- ▶ TCSI: Taiwan Chemical Substance Inventory
- ▶ INSQ: Inventario Nacional de Sustancias Químicas
- ▶ NCI: National Chemical Inventory
- ▶ FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.
Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.
TEL (+61 3) 9572 4700.